Nutriband Inc. announced it has received a Notice of Allowance from the USPTO for its patent application regarding the Aversa™ abuse deterrent technology, which is designed to prevent the misuse and ...

Nutriband granted patent protecting its AVERSA abuse deterrent platform technology in Macao, a Special Administrative Region of the People’s Republic of China ORLANDO, Fla., April 11, 2025 (GLOBE ...

ORLANDO, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced ...

ORLANDO, Fla., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) has provided an update to shareholders on the key milestones and discussions from this years Annual ...

Nutriband (NTRB) files provisional patent application to enhance its AVERSA™ transdermal abuse deterrent technology being developed for patches containing opioids and stimulants with a potential for ...

This technology can be incorporated into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse deterrent technology is ...

ORLANDO, FL / ACCESSWIRE / March 28, 2023 / Nutriband Inc. ("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) has entered into a three-year $2,000,000 Credit Line facility to provide financing through the FDA ...

Nutriband’s abuse-deterrent platform technology is now patented in 46 countries and territories covering major global markets. Nutriband (NTRB) is targeting to file for FDA approval for AVERSA™ ...

Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for the patent application covering its Platform AVERSA™ abuse deterrent transdermal technology ...